ReviewArthritis research2002
Angiogenesis in rheumatoid arthritis.
Review in Arthritis research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it, 341 citations in OpenAlex.
- The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets.Arthritis research & therapy · 2009Pooled it
- Targeting NAV2-mediated Wnt/β-catenin signaling in rheumatoid arthritis: current evidence and emerging therapeutic approaches.Molecular biology reports · 2026Review
- Effects of Pelargonium sidoides root extract on paw oedema, nitric oxide signaling, and synovial vascular changes in a rat model of adjuvant-induced arthritis.Inflammopharmacology · 2026Article
- Angiogenic markers in difficult-to-treat psoriatic arthritis.Frontiers in immunology · 2026Article
- Cytokine-mediated pathophysiology of equine and human joint disease: mechanisms, biomarkers, and therapeutic targets.Frontiers in veterinary science · 2026Review
- Multi-pathway regulatory role of miR-4693-5p in the modulation of rheumatoid arthritis.Scientific reports · 2025Article
- Ginsenoside compound K-based multifunctional liposomes for the treatment of rheumatoid arthritis.Drug delivery · 2025Article
- The distinct transcriptomic signature of the resolution phase fibroblast-like synoviocytes supports endothelial cell dysfunction.Communications biology · 2025Article
- Monitoring microvascular changes over time with a repositionable 3D ultrasonic capacitive micromachined row-column sensor.Science advances · 2025Article
- Review
- Translation of cell therapies to treat autoimmune disorders.Advanced drug delivery reviews · 2024Review
- Phytochemicals Showing Antiangiogenic Effect in Pre-clinical Models and their Potential as an Alternative to Existing Therapeutics.Current topics in medicinal chemistry · 2024Review
- The protective effect of natural medicines in rheumatoid arthritis via inhibit angiogenesis.Frontiers in pharmacology · 2024Review
- Review
- Geraniol Suppresses Oxidative Stress, Inflammation, and Interstitial Collagenase to Protect against Inflammatory Arthritis.ACS omega · 2023Article
- The Mechanisms and Efficacy of Photobiomodulation Therapy for Arthritis: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways.International journal of molecular sciences · 2023Review
- Inflammatory Mesenchymal Stem Cells Express Abundant Membrane-Bound and Soluble Forms of C-Type Lectin-like CD248.International journal of molecular sciences · 2023Article
- MMP-13, VEGF, and Disease Activity in a Cohort of Rheumatoid Arthritis Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Computational Fluid Dynamics (CFD) Model for Analysing the Role of Shear Stress in Angiogenesis in Rheumatoid Arthritis.International journal of molecular sciences · 2023Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expansion of the synovial lining of joints in rheumatoid arthritis (RA) and the subsequent invasion by the pannus of underlying cartilage and bone necessitate an increase in the vascular supply to the synovium, to cope with the increased requirement for oxygen and nutrients. The formation of new blood vessels - termed 'angiogenesis' - is now recognised as a key event in the formation and maintenance of the pannus in RA. This pannus is highly vascularised, suggesting that targeting blood vessels in RA may be an effective future therapeutic strategy. Disruption of the formation of new blood vessels would not only prevent delivery of nutrients to the inflammatory site, but could also lead to vessel regression and possibly reversal of disease. Although many proangiogenic factors are expressed in the synovium in RA, the potent proangiogenic cytokine vascular endothelial growth factor (VEGF) has been shown to a have a central involvement in the angiogenic process in RA. The additional activity of VEGF as a vascular permeability factor may also increase oedema and hence joint swelling in RA. Several studies have shown that targeting angiogenesis in animal models of arthritis ameliorates disease. Our own study showed that inhibition of VEGF activity in murine collagen-induced arthritis, using a soluble VEGF receptor, reduced disease severity, paw swelling, and joint destruction. Although no clinical trials of anti-angiogenic therapy in RA have been reported to date, the blockade of angiogenesis - and especially of VEGF - appears to be a promising avenue for the future treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.